TOP2A and central nervous system cancer: Previous research has shown that its expression is significantly downregulated in osteosarcoma [21], lung cancer [22], prostate cancer [23] and glioblastoma [24,25].However, the molecular mechanism that regulates TOP2A expression is still unclear for HCMV-positive glioma.